Abstract
Aims
Aortic valve stenosis (AS) results in higher systolic pressure to overcome resistance from the stenotic valve, leading to heart failure and decline in cardiac output. There has been no assessment of cerebral blood flow (CBF) association with neurocognition in AS or the effects of valve replacement. The goal was to determine if AS is associated with altered cerebral haemodynamics and impaired neurocognition, and whether transcatheter aortic valve replacement (TAVR) improves haemodynamics and cognition.
Methods and results
In 42 patients with planned TAVR, transcranial Doppler (TCD) assessed bilateral middle cerebral artery (MCA) mean flow velocities (MFVs); abnormality was <34.45 cm/s. The neurocognitive battery assessed memory, language, attention, visual–spatial skills, and executive function, yielding a composite Z-score. Impairment was <1.5 SDs below the normative mean. The mean age was 78 years, 59% Male, and the mean valve gradient was 46.87 mm/Hg. Mean follow-up was 36 days post-TAVR (range 27–55). Pre-TAVR, the mean MFV was 42.36 cm/s (SD = 10.17), and the mean cognitive Z-score was −0.22 SDs (range −1.99 to 1.08) below the normative mean. Among the 34 patients who returned after TAVR, the MFV was 41.59 cm/s (SD = 10.42), not different from baseline (P = 0.66, 2.28–3.67). Post-TAVR, average Z-scores were 0.17 SDs above the normative mean, not meeting the pre-specified threshold for a clinically significant 0.5 SD change.
Conclusion
Among patients with severe AS, there was little impairment of MFV on TCD and no correlation with cognition. Transcatheter aortic valve replacement did not affect MFV or cognition. Assumptions about diminished CBF and improvement after TAVR were not supported.
Keywords: Aortic valve stenosis, TAVR, Cerebral blood flow, Neurocognition
Graphical Abstract
Graphical Abstract.
The relationship of cognition (Z-scores) to cerebral haemodynamics (mean flow velocity). Abnormality: ≥1.50 SD below normative means.
Introduction
Transcatheter aortic valve replacement (TAVR) is a treatment for severe aortic stenosis (AS).1 Previous studies of TAVR and the brain have involved ischaemic injury2 but lacked cerebral haemodynamics [cerebral blood flow (CBF)] and its relationship with cognition. We wanted to determine if TAVR benefits the brain.
Methods
Patients
Patients enrolled at the University of Alabama at Birmingham Medical Center and the Columbia University Irving Medical Center. Institutional review boards approved this study; participants signed informed consent.
Inclusions included severe AS (mean pressure gradient >40 mmHg, peak velocity >4.0 m/s, and valve area <1.0 cm, either at rest or with dobutamine); planned TAVR; and English fluency. Exclusions were prior major stroke, known carotid disease, uncontrolled vascular risk factors, severe pulmonary disease, and inadequate sonographic windows for transcranial Doppler (TCD).
Participants underwent the Mini-Mental State Exam for frank dementia; ineligibility was ≤23/30.
Measurement of haemodynamics
Patients underwent transthoracic echocardiography and had severe AS per the American College of Cardiology valvular heart disease guidelines.3 The TCD equipment was certified by the Intersocietal Accreditation Commission. Using a standard headframe, middle cerebral arteries were located through the temporal windows bilaterally at a depth of 50–56 mm using 2 MHz probes. After stability of waveforms, mean flow velocity (MFV) was acquired bilaterally over the next 2 min and averaged. If bone windows could not be obtained for either middle cerebral artery (MCA), values came from the remaining MCA. Abnormal MVFs were ≤34.5 cm/s.4
Neurocognitive testing
There were nine standardized neuropsychological tests used previously in the Sentinel trial for TAVR5 and aligned with recent Neurologic Academic Research Consortium guidelines.6 The test battery (Table 1) was scored centrally, blinded of TCD findings.
Table 1.
The neuropsychological test battery
Neurocognitive test | Domain |
---|---|
Trail Making Part A | Attention |
Digit Span | Attention |
Trail Making Part B | Executive function |
Rey Complex Figure (copy) | Executive function |
Digit Symbol | Processing speed |
Controlled Oral Word Association | Processing speed |
Hopkins Verbal Learning Test | Verbal memory |
Brief Visual Memory Test | Visual memory |
Z-scores were calculated from normative means and standard deviations for each neurocognitive test. Higher Z-scores represent better function. The composite cognitive Z-score was the average Z-score of all domains. Abnormality was −1.5 SD below the normative mean.7 A clinically significant change in cognition was pre-defined as a 0.5 SD change from baseline.8
Statistical analysis
t-tests and Spearman’s correlation coefficients were used. Tests with multiple observations (e.g. individual cognitive domain score) had Bonferroni correction at P = 0.01.
Results
Seventy participants signed informed consent of whom we assessed 42 at baseline and 34 after TAVR for TCD and 31 with neurocognitive assessment. Four failed the dementia assessment. There was a mean of 6.38 days between baseline assessment and TAVR. Table 2 displays demographics. There were no demographic, baseline TCD, or neurocognitive differences between those who were and were not seen in follow-up.
Table 2.
Patient demographics
Demographics | |
---|---|
n | 42 |
Age mean (range) | 78 (52–93) |
Education mean [years (SD)] | 14 (3.6) |
Male [n (%)] | 24 (59) |
Race [Caucasian n (%)] | 39 (93) |
STS [PROM (mean (SD)] surgical mortality score | 3.91 (1.87) |
Valve area [cm2; mean (SD)] | 0.75 (0.21) |
Mean aortic valve gradient [mmHg (SD)] | 46.87 (10.67) |
LVEF (<50%) | 2 |
Mean arterial pressure [mean (SD)] | 92.21 (19.1) |
Hx of stroke (%) | 2 |
Hx of TIA (%) | 2 |
Hx of hypertension (%) | 90 |
Hx of diabetes (%) | 43 |
Hx of dyslipidaemia (%) | 69 |
Hx of Afib (%) | 31 |
NYHA Class III (%) | 8 |
STS (PROM), The society of thoracic surgeons predicted risk of mortality; LVEF, left ventricular ejection fraction; TIA, transient ischemic attack; Afib, atrial fibrillation; NYHA, New York State Heart Association.
Before TAVR, average MFV was 42.36 cm/s (SD 10.17), with 2/42 having impaired CBF velocities. The mean composite cognitive baseline Z-score was −0.25 SD below normative mean. Neither the overall mean composite Z-score nor the individual domain scores were in the impaired range. Among individual patients, 6/42 were impaired. Two patients missed their pre-procedure cognitive assessments. Figure 1 displays the composite Z-scores and MFV in the MCAs, along with the designation of impairment. There was a non-significant negative correlation (r = −03.11, P = 0.115). Of the six patients with impaired cognition, none had abnormal MFVs. Of the two patients with abnormal MFVs, neither had abnormal cognition.
Figure 1.
Mean composite Z-scores and cerebral blood flow before transcatheter aortic valve replacement. Abnormality: ≥1.5 SD below the normative means for cognition and for mean flow velocity. MCA, middle cerebral artery..
Thirty-four patients returned for the post-TAVR follow-up; the mean follow-up period was 36 days. At follow-up, the average MFV was 41.59 cc/s (SD = 10.42), not statistically different from average baseline MFVs [P = 0.66 (−2.38 to 3.67)]. After TAVR, the mean composite cognitive Z-score was 0.17 SD above the normative mean, a statistically significant change from baseline but not meeting the 0.5 SD threshold for clinical improvement.
Discussion
We found little impairment in MFV on TCD in the middle cerebral artery prior to or after TAVR. There was no correlation between baseline MFV and neurocognition. Although there was a statistically significant improvement in neurocognition from pre- to post-TAVR, the pre-established criterion for a clinically relevant change was not met. Thus, we found no evidence that AS has an impact on CBF and a corresponding cognitive effect.
That TAVR might increase cerebral flood flow was based on the premise that post-procedure cognitive improvement may have been from increased haemodynamics across the new aortic valve. Another study measured CBF of the total grey matter quantified by arterial spin labelling (ASL) with 3 T MRI.9 Their increase in perfusion was from 42.5 to 43.8 mL/100 g/min over the entire brain, findings similar to ours, despite improved cardiac output, which was not statistically significant (P = 0.41).
Cerebral blood flow is governed by autoregulation that expands and contracts vessels with alterations of perfusion and the extraction of a percentage of oxygen from the blood supply, which increases only when autoregulatory capacity has been exhausted.10 Our data showed normal-range MFV on TCD at baseline, suggesting that impaired flow across the stenotic aortic valve is not sufficient to exceed the brain’s autoregulatory capacity.
Limitations
The N was relatively small, but our sample was representative of the TAVR population with intermediate risk. Our results may not generalize to more severe AS cases. There was no control group, but we could not ethically delay or preclude TAVR for whom there was a clinical indication for treatment. Little change on TCD after TAVR reduced the likelihood of measurement variability of blood flow. A third limitation was that the 30-day follow-up may not have been long enough to demonstrate a cerebral haemodynamic impact. We did not measure more subtle changes in cerebral haemodynamics, such as vasomotor reactivity, flow acceleration, or dynamic cerebral autoregulation, and we recognize that MVF is only a surrogate for cerebral perfusion.
Our goal was not to show the prevalence of cerebral haemodynamics of those undergoing TAVR but to determine whether CBF was independently related to AS and improved after valve replacement. These findings suggest that cerebral haemodynamic mechanisms are sufficient to maintain cognition in the setting of this disease.
Contributor Information
Ronald M Lazar, Department of Neurology, University of Alabama at Birmingham, 1720 7th Avenue South, SC650K, Birmingham, AL 35294, USA; Department of Neurology, Columbia University Irving Medical Center, 710 W168th Street, NewYork, NY 10032, USA.
Terina Myers, Department of Neurology, University of Alabama at Birmingham, 1720 7th Avenue South, SC650K, Birmingham, AL 35294, USA.
Toby I Gropen, Department of Neurology, University of Alabama at Birmingham, 1720 7th Avenue South, SC650K, Birmingham, AL 35294, USA.
Massoud A Leesar, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
James Davies, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Adam Gerstenecker, Department of Neurology, University of Alabama at Birmingham, 1720 7th Avenue South, SC650K, Birmingham, AL 35294, USA.
Amani Norling, Department of Neurology, University of Alabama at Birmingham, 1720 7th Avenue South, SC650K, Birmingham, AL 35294, USA.
Marykay A Pavol, Department of Neurology, Columbia University Irving Medical Center, 710 W168th Street, NewYork, NY 10032, USA.
Randolph S Marshall, Department of Neurology, Columbia University Irving Medical Center, 710 W168th Street, NewYork, NY 10032, USA.
Susheel Kodali, Department of Medicine, Columbia University Irving Medical Center, NewYork, NY, USA.
Lead author biography
Ronald M. Lazar, PhD, FAAN, FAHA, holds the Evelyn F. McKnight Endowed Chair and is a Professor of Neurology and Neurobiology and Director of the UAB McKnight Brain Institute at the University of Alabama at Birmingham in the USA. His research, largely funded by the US National Institutes of Health, focuses on the relationship between neurocognition, and cardiovascular and cerebrovascular disease. Prior to joining UAB in 2017, he was a Professor of Neuropsychology in Neurology and Neurosurgery at the Columbia University College of Physicians & Surgeons in New York City and the New York Neurological Institute.
Data availability
The data are available for sharing through a request to the corresponding author.
Funding
This research was supported in part by a joint grant (1R21NS096972-01A1) by the National Institute of Neurological Disorders and Stroke and The National Institute of Aging of the United States National Institutes of Health.
References
- 1. Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, Derumeaux G, Anselme F, Laborde F, Leon MB. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 2002;106:3006–3008. [DOI] [PubMed] [Google Scholar]
- 2. Schaff HV. Transcatheter aortic-valve implantation—at what price? N Engl J Med 2011;364:2256–2258. [DOI] [PubMed] [Google Scholar]
- 3. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Guyton RA, O'Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM, Thomas JD. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2438–2488. [DOI] [PubMed] [Google Scholar]
- 4. Marshall RS, Pavol MA, Cheung YK, Strom I, Slane K, Asllani I, Lazar RM. Dissociation among hemodynamic measures in asymptomatic high grade carotid artery stenosis. J Neurol Sci 2016;367:143–147. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Lazar RM, Pavol MA, Bormann T, Dwyer MG, Kraemer C, White R, Zivadinov R, Wertheimer JC, Thöne-Otto A, Ravdin LD, Naugle R, Mechanic-Hamilton D, Garmoe WS, Stringer AY, Bender HA, Kapadia SR, Kodali S, Ghanem A, Linke A, Mehran R, Virmani R, Nazif T, Parhizgar A, Leon MB. Neurocognition and cerebral lesion burden in high-risk patients before undergoing transcatheter aortic valve replacement: insights from the SENTINEL trial. JACC Cardiovasc Interv 2018;11:384–392. [DOI] [PubMed] [Google Scholar]
- 6. Lansky AJ, Messe SR, Brickman AM, Dwyer M, van der Worp HB, Lazar RM, Pietras CG, Abrams KJ, McFadden E, Petersen NH, Browndyke J, Prendergast B, Ng VG, Cutlip DE, Kapadia S, Krucoff MW, Linke A, Moy CS, Schofer J, van Es GA, Virmani R, Popma J, Parides MK, Kodali S, Bilello M, Zivadinov R, Akar J, Furie KL, Gress D, Voros S, Moses J, Greer D, Forrest JK, Holmes D, Kappetein AP, Mack M, Baumbach A. Proposed standardized neurological endpoints for cardiovascular clinical trials: an academic research consortium initiative. J Am Coll Cardiol 2017;69:679–691. [DOI] [PubMed] [Google Scholar]
- 7. Meyer AC, Boscardin WJ, Kwasa JK, Price RW. Is it time to rethink how neuropsychological tests are used to diagnose mild forms of HIV-associated neurocognitive disorders? Impact of false-positive rates on prevalence and power. Neuroepidemiology 2013;41:208–216. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Manly JJ, Tang MX, Schupf N, Stern Y, Vonsattel JP, Mayeux R. Frequency and course of mild cognitive impairment in a multiethnic community. Ann Neurol 2008;63:494–506. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Vlastra W, van Nieuwkerk AC, Bronzwaer AGT, Versteeg A, Bron EE, Niessen WJ, Mutsaerts HJMM, van der Ster BJP, Majoie CBLM, Biessels GJ, Nederveen AJ, Daemen MJAP, van Osch MJP, Baan J, Piek JJ, Van Lieshout JJ, Delewi R. Cerebral blood flow in patients with severe aortic valve stenosis undergoing transcatheter aortic valve implantation. J Am Geriatr Soc 2021;69:494–499. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Derdeyn CP, Videen TO, Yundt KD, Fritsch SM, Carpenter DA, Grubb RL, Powers WJ. Variability of cerebral blood volume and oxygen extraction: stages of cerebral haemodynamic impairment revisited. Brain 2002;125:595–607. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The data are available for sharing through a request to the corresponding author.